Curcumin, a polyphenolic compound derived from Curcuma longa, has been widely studied for its anticancer properties, including its potential to inhibit BCR-ABL signaling in CML. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.